TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on "TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD".
作者信息
Caddeo Andrea, Mancina Rosellina M
机构信息
Department of Biomedical Sciences, Unit of Oncology and Molecular Pathology, University of Cagliari, Cagliari, Italy.
Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy.
出版信息
Clin Mol Hepatol. 2025 Jan;31(1):293-296. doi: 10.3350/cmh.2024.0703. Epub 2024 Aug 27.
Abstract
摘要
相似文献
1
TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on "TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD".TM6SF2和PNPLA3：一对潜在的活力组合？：关于“TM6SF2 E167K变体减少PNPLA3介导的多不饱和脂肪酸转移以促进非酒精性脂肪性肝炎相关脂肪性肝病中的肝脂肪变性和损伤”的社论
Clin Mol Hepatol. 2025 Jan;31(1):293-296. doi: 10.3350/cmh.2024.0703. Epub 2024 Aug 27.
2
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD.TM6SF2 E167K 变异体降低 PNPLA3 介导的多不饱和脂肪酸转移，从而促进 MASLD 中的肝脂肪变性和损伤。
Clin Mol Hepatol. 2024 Oct;30(4):863-882. doi: 10.3350/cmh.2024.0268. Epub 2024 Jul 26.
3
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on "TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD".PNPLA3是TM6SF2 E167K变异体与代谢相关脂肪性肝病（MASLD）之间的桥梁之一：对应于关于“TM6SF2 E167K变异体减少PNPLA3介导的多不饱和脂肪酸转运以促进MASLD中的肝脂肪变性和损伤”的社论 。
Clin Mol Hepatol. 2025 Jan;31(1):e67-e69. doi: 10.3350/cmh.2024.0744. Epub 2024 Sep 10.
4
Deep metabolic phenotyping of humans with protein-altering variants in using a genome-first approach.使用基因组优先方法对具有蛋白质改变变体的人类进行深度代谢表型分析。
JHEP Rep. 2024 Oct 11;7(1):101243. doi: 10.1016/j.jhepr.2024.101243. eCollection 2025 Jan.
5
Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.TM6SF2 E167K 和 PNPLA3 I148M 变异体在东北地区非酒精性脂肪性肝病中的相互作用。
Ann Hepatol. 2019 May-Jun;18(3):456-460. doi: 10.1016/j.aohep.2018.10.005. Epub 2019 Apr 15.
6
TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.TM6SF2 E167K变异与慢性丙型肝炎的严重脂肪变性相关，与PNPLA3基因多态性无关。
Liver Int. 2015 Aug;35(8):1959-63. doi: 10.1111/liv.12781. Epub 2015 Jan 27.
7
Relevance of , , , and Variants to MASLD Severity in an Egyptian Population.[具体基因名称]、[具体基因名称]、[具体基因名称]和[具体基因名称]变体与埃及人群中代谢相关脂肪性肝病严重程度的相关性
Genes (Basel). 2024 Apr 4;15(4):455. doi: 10.3390/genes15040455.
8
Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus.PNPLA3和TM6SF2基因多态性对非酒精性脂肪性肝病合并2型糖尿病患者预后的影响。
Liver Int. 2024 Apr;44(4):1042-1050. doi: 10.1111/liv.15845. Epub 2024 Jan 31.
9
Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.PNPLA3基因rs738409、TM6SF2基因rs58542926和MBOAT7基因rs641738变异对非酒精性脂肪性肝病严重程度的联合影响：一项基于多中心活检的研究。
J Lipid Res. 2017 Jan;58(1):247-255. doi: 10.1194/jlr.P067454. Epub 2016 Nov 11.
10
Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.载脂蛋白基因 I148M 及 TM6SF2 基因 E167K 变异与非酒精性脂肪性肝病患者冠心病风险的独立及联合相关性。
Lipids Health Dis. 2020 Feb 24;19(1):29. doi: 10.1186/s12944-020-01207-9.
引用本文的文献
1
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on "TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD".PNPLA3是TM6SF2 E167K变异体与代谢相关脂肪性肝病（MASLD）之间的桥梁之一：对应于关于“TM6SF2 E167K变异体减少PNPLA3介导的多不饱和脂肪酸转运以促进MASLD中的肝脂肪变性和损伤”的社论 。
Clin Mol Hepatol. 2025 Jan;31(1):e67-e69. doi: 10.3350/cmh.2024.0744. Epub 2024 Sep 10.
本文引用的文献
1
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD.TM6SF2 E167K 变异体降低 PNPLA3 介导的多不饱和脂肪酸转移，从而促进 MASLD 中的肝脂肪变性和损伤。
Clin Mol Hepatol. 2024 Oct;30(4):863-882. doi: 10.3350/cmh.2024.0268. Epub 2024 Jul 26.
2
3D culture models to study pathophysiology of steatotic liver disease.三维培养模型研究脂肪变性肝病的病理生理学。
Atherosclerosis. 2024 Jun;393:117544. doi: 10.1016/j.atherosclerosis.2024.117544. Epub 2024 Apr 15.
3
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
4
The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans.载脂蛋白基因 PNPLA3 I148M 变异可增加酮体生成，减少肝内从头合成脂和线粒体功能。
Cell Metab. 2023 Nov 7;35(11):1887-1896.e5. doi: 10.1016/j.cmet.2023.10.008. Epub 2023 Oct 30.
5
MBOAT7 in liver and extrahepatic diseases.MBOAT7 在肝脏和肝外疾病中的作用。
Liver Int. 2023 Nov;43(11):2351-2364. doi: 10.1111/liv.15706. Epub 2023 Aug 22.
6
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家组关于新的脂肪肝疾病命名的德尔菲共识声明。
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
7
Preparing for the NASH epidemic: A call to action.应对 NASH 流行的准备：行动呼吁。
Obesity (Silver Spring). 2021 Sep;29(9):1401-1412. doi: 10.1002/oby.23250. Epub 2021 Aug 8.
8
Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.TM6SF2 E167K对人类肝脏脂质及极低密度脂蛋白代谢的影响。
JCI Insight. 2020 Dec 17;5(24):144079. doi: 10.1172/jci.insight.144079.
9
The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids.TM6SF2 E167K 基因变异可诱导人肝 3D 球体中的脂质生物合成并降低载脂蛋白 B 的分泌。
Sci Rep. 2019 Aug 12;9(1):11585. doi: 10.1038/s41598-019-47737-w.
10
Patatin-like phospholipase domain–containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets.载脂蛋白样磷脂酶结构域蛋白 3 促进肝脏脂滴中必需脂肪酸从甘油三酯向磷脂的转移。
J Biol Chem. 2018 May 4;293(18):6958-6968. doi: 10.1074/jbc.RA118.002333. Epub 2018 Mar 19.
Zotero 插件